The selling is too small to read through as a bearish signal — it likely reflects routine diversification or tax planning. Monitor for any upcoming earnings or pipeline catalyst that would give these sales more context. No immediate trading action warranted.
Price Chart
Executive Summary
Two insiders at Oruka Therapeutics—General Counsel Paul Quinlan and Director Carl Dambkowski—sold a combined $933K in open-market transactions over four days. While the insider cluster is selling, the total value is only ~0.02% of the company's $4.2B market cap, making the signal economically trivial. The cross-filing actuarial verdicts strongly amplify the cluster-earnings-context and cluster-insider-trades pair, but neither earnings nor other material cross-filings are present in the actual context provided, so the amplifiers fire without a substantive base event.
Key Financial Metrics
Key Facts
- Cluster comprises 2 insiders selling over 4-day window (June 11–15, 2026)
- Total open-market sales: $933K, roughly 0.02% of ORKA's $4.2B market cap
- Director Dambkowski sold 35K shares combined for ~$2.45M; General Counsel Quinlan sold 733 shares for $51K
- No earnings, offering, or material corporate event cross-filings present to provide informational context
- Institutional ownership heavy (Fidelity $365M, BlackRock $173M) with net accumulation pattern (6 adds vs 5 trims)
Financial Impact
Insider sales of $933K represent a de minimis 0.02% of market cap; no material financial impact
Risk Factors
- If future filings reveal an unannounced negative catalyst (e.g., trial failure, regulatory delay), these sales could appear prescient in hindsight
- Director Dambkowski's sales at ~$70 are near the current price; further acceleration above 0.5% of market cap would be more concerning
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1781563855572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access